Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC — Stella

Recruiting

Back to Metastatic Prostate Cancer trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Urology dpt, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu

Key details

Phase

Large-scale testing

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Enrollment target

~200 participants

Started

December 2023

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

40 Years – 80 Years

Sex

Male only

Last updated December 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov